Sigma-1 Receptor Ligands for CNS Cancer Treatment

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Conventional cancer therapies face challenges like nonspecificity, multidrug resistance, and poor blood-brain barrier (BBB) penetration for central nervous system (CNS) cancers.
• Sigma receptors, particularly sigma-1, are implicated in neurodegeneration and pain, and are overexpressed in many cancers, yet their anticancer potential is underexplored.
• Sigma receptors regulate crucial cancer processes including cell survival, proliferation, differentiation, and autophagy.

Purpose of the Study:

• To explore the potential of repurposing existing neuroactive drugs as anticancer agents, focusing on their sigma receptor activity.
• To investigate the role of sigma-1 receptor ligands in modulating autophagy for cancer treatment, particularly CNS cancers.
• To review the autophagic, anticancer, and sigma-receptor activities of specific neuroactive drugs like haloperidol, rimcazole, fluoxetine, and donepezil.

Main Methods:

• Literature review of studies on sigma receptor ligands and their effects on cancer cells.
• Analysis of existing neuroactive drugs (haloperidol, rimcazole, fluoxetine, donepezil) for their sigma receptor binding and anticancer properties.
• Examination of the link between sigma-1 receptor modulation, autophagy, and cancer progression.

Main Results:

• Sigma receptors are promising therapeutic targets due to their role in cell survival, proliferation, and differentiation.
• Sigma-1 receptor activity is linked to the regulation of autophagy, a key process in cancer development.
• Several neuroactive drugs acting as sigma receptor ligands show potential anticancer benefits, including for CNS cancers.

Conclusions:

• Drug repurposing of sigma receptor ligands presents a cost-effective and time-efficient approach to developing novel anticancer therapies.
• Neuroactive drugs targeting sigma receptors may overcome challenges associated with conventional cancer treatments, including drug resistance and BBB penetration.
• Further research into sigma receptor-modulating drugs could lead to effective treatments for various cancers, especially those affecting the CNS.